• Explore /
  • Poster
  • / NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumor mutation burden for high-risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.

NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumor mutation burden for high-risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.

Abstract Poster

Authors

Kai-Keen Shiu

Kai-Keen Shiu

University College Hospital, NHS Foundation Trust, London, United Kingdom

Kai-Keen Shiu , Jenny F. Seligmann , Janet Graham , Richard H. Wilson , Mark P. Saunders , Timothy Iveson , Hamzeh Kayhanian , Khurum H. Khan , Manuel Rodriguez-Justo , Marnix Jansen , Austin Obichere , Andrew Plumb , Edward Seward , Sandra Irvine , William Wilson , Reshma Bhat , Sharon Forsyth , Laura White

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer - Neo-Adjuvant/Adjuvant

Clinical Trial Registration Number

NCT05197322

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS3645)

DOI

10.1200/JCO.2022.40.16_suppl.TPS3645

Abstract #

TPS3645

Poster Bd #

430b

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Assessment of complete pathologic response after neoadjuvant immunotherapy for MSI-H gastrointestinal cancers.

Assessment of complete pathologic response after neoadjuvant immunotherapy for MSI-H gastrointestinal cancers.

First Author: Kruti Bhagirath Vora

First Author: Matt D. Galsky

First Author: Naixin Ding

First Author: Hui-Chuan Sun